Scalper1 News
Generic-drug maker and IBD 50 stock Akorn (AKRX) reported Q4 earnings and gave 2015 guidance above consensus Thursday, sending the stock up nearly 12% on the stock market today to a new high near 52. Akorn’s earnings excluding one-time items jumped 257% over the year-earlier quarter to 50 cents a share, topping analysts’ consensus by 5 cents, according to Thomson Reuters. Sales climbed 168% to $227.8 million, about $10 million above the Street’s Scalper1 News
Scalper1 News